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and NF-κB in colorectal cancer * 
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 BACKGROUND: The ubiquitin-proteasome pathway is important in regulating protein 
signaling pathways that are involved in tumorigenesis. β-transducin repeat-containing proteins 
(β-TrCP) are components of the ubiquitin ligase complex targeting β-catenin and IκBα for 
proteasomal degradation and are thus a negative regulator of Wnt/β-catenin signaling and a 
positive regulator of NF-κB signaling. We analyzed expression of β-TrCP in colorectal cancers 
and its association with types of β-catenin subcellular localization, an indirect measure of 
activation. METHODS: Levels of β-TrCP1 mRNA and protein were measured by quantitative 
reverse transcription-polymerase chain reaction and immunoblotting, respectively, in samples of 
tumor and normal tissues from 45 patients with colorectal cancer. Types of β-catenin activation 
(diffuse or invasion edge) and NF-κB activation were examined by immunohistochemistry. 
Apoptosis was determined by the terminal deoxynucleotidyl transferase-mediated deoxyuridine 
triphosphate-biotin nick-end labeling (TUNEL) assay. All statistical tests were two-sided. 
RESULTS: Compared with the β-TrCP1 levels in normal tissues, 25 (56%) of 45 tumors had 
increased β-TrCP1 mRNA and protein levels. Of the 22 (49%) tumors with β-catenin activation, 
12 had the diffuse type (i.e., nuclear accumulation throughout the tumor) and 10 had the 
invasion edge type (i.e., nuclear accumulation predominantly in the tumor cells that formed the 
invasion edge). Increased β-TrCP1 levels were statistically significantly associated with 
β-catenin activation (P =.023) and decreased apoptosis (P =.035). β-TrCP accumulated in the 
nuclei of tumor cells that contained increased levels of β-TrCP1 mRNA and the active form of 
NF-κB. Higher levels of β-TrCP1 mRNA were detected in primary tumors of patients who had 
metastases (0.960 arbitrary units, 95% confidence interval = 0.878 to 1.042) than in the tumors 
of patients who did not (0.722 arbitrary units, 95% confidence interval = 0.600 to 0.844; P 
=.016). CONCLUSION: In colorectal cancer, increased expression of β-TrCP1 is associated 
with activation of both β-catenin and NF-κB, suggesting that the integration of these signaling 
pathways by increased β-TrCP expression may contribute to an inhibition of apoptosis and 
tumor metastasis. 
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